Gene: Pygl (glycogen phosphorylase L) Rattus norvegicus
Analyze
Symbol:
Pygl
Name:
glycogen phosphorylase L
Description:
Exhibits several functions, including carbohydrate binding activity; glycogen phosphorylase activity; and identical protein binding activity. Involved in 5-phosphoribose 1-diphosphate biosynthetic process and glycogen catabolic process. Localizes to the cytoplasm. Human ortholog(s) of this gene implicated in glycogen storage disease and glycogen storage disease VI. Orthologous to human PYGL (glycogen phosphorylase L); PARTICIPATES IN glycogen degradation pathway; glycogen metabolic pathway; congenital sucrase-isomaltase deficiency pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 17alpha-ethynylestradiol; 17beta-estradiol.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
glycogen phosphorylase; glycogen phosphorylase, liver form; liver glycogen phosphorylase; phosphorylase, glycogen, liver
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
PYGL (glycogen phosphorylase L) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Mus musculus (house mouse):
Pygl (liver glycogen phosphorylase) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Pygl (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Pygl (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Other homologs 2
Homo sapiens (human):
PYGB (glycogen phosphorylase B) HGNC
OrthoMCL
Homo sapiens (human):
PYGM (glycogen phosphorylase, muscle associated) HGNC
OrthoMCL
Alliance orthologs 3
Homo sapiens (human):
PYGL (glycogen phosphorylase L)
Alliance
DIOPT (Ensembl Compara, HGNC, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Mus musculus (house mouse):
Pygl (liver glycogen phosphorylase)
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Danio rerio (zebrafish):
pygl (phosphorylase, glycogen, liver)
Alliance
DIOPT (Ensembl Compara, OMA, OrthoFinder, PANTHER, PhylomeDB, TreeFam)
Saccharomyces cerevisiae (baker's yeast):
GPH1
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Drosophila melanogaster (fruit fly):
GlyP
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Caenorhabditis elegans (roundworm):
pygl-1
Alliance
DIOPT (Ensembl Compara, Hieranoid, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, PhylomeDB, TreeFam)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 6 92,597,759 - 92,643,734 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 6 92,597,706 - 92,643,847 (-) Ensembl Rnor_5.0 6 102,045,144 - 102,091,119 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 6 92,298,339 - 92,341,347 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 6 92,301,796 - 92,344,803 (-) NCBI Celera 6 87,191,869 - 87,228,313 (-) NCBI Celera Cytogenetic Map 6 q24 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Disease Annotations
Imported Annotations - ClinVar
glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:25741868 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:12809646 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:21646031 more ... glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:25266922 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:22899091 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:17705025 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:17705025 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:21646031 more ... glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:24033266 , PMID:25741868 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:25741868 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar PMID:9536091 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar PMID:9529348 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar PMID:24033266 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:17705025 , PMID:25741868
Imported Annotations - CTD
Chemical and Drug Induced Liver Injury ISO RGD:731803 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:25231249 glycogen storage disease VI ISO RGD:731803 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:9529348 , PMID:9536091 hepatocellular carcinoma ISO RGD:731803 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:2885971 Imported Annotations - OMIM
glycogen storage disease VI ISO RGD:731803 7240710 OMIM
1,1-dichloroethene decreases expression ISO RGD:731804 6480464 vinylidene chloride results in decreased expression of PYGL mRNA CTD PMID:26682919 1,2-dichloroethane decreases expression ISO RGD:731804 6480464 ethylene dichloride results in decreased expression of PYGL mRNA, ethylene dichloride results in decreased expression of PYGL protein CTD PMID:28189721 1-naphthyl isothiocyanate decreases expression EXP 6480464 1-Naphthylisothiocyanate results in decreased expression of PYGL mRNA CTD PMID:17522070 17alpha-ethynylestradiol multiple interactions ISO RGD:731804 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PYGL mRNA CTD PMID:17942748 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of PYGL mRNA CTD PMID:17557909 17beta-estradiol decreases expression ISO RGD:731804 6480464 Estradiol results in decreased expression of PYGL mRNA CTD PMID:19484750 17beta-estradiol multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of PYGL mRNA CTD PMID:26496021 1H-pyrazole decreases expression ISO RGD:731804 6480464 pyrazole results in decreased expression of PYGL mRNA CTD PMID:17945193 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:731804 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PYGL mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:731804 6480464 Tetrachlorodibenzodioxin results in decreased expression of PYGL mRNA CTD PMID:19770486 , PMID:27562557 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:731803 6480464 Tetrachlorodibenzodioxin results in increased expression of PYGL mRNA CTD PMID:22903824 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of PYGL mRNA CTD PMID:20959002 , PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:731804 6480464 Tetrachlorodibenzodioxin affects the expression of PYGL mRNA CTD PMID:21570461 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of PYGL mRNA CTD PMID:21346803 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of PYGL mRNA CTD PMID:21346803 2-hydroxypropanoic acid decreases expression ISO RGD:731803 6480464 Lactic Acid results in decreased expression of PYGL mRNA CTD PMID:30851411 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:27509375 , PMID:29474705 3-chloropropane-1,2-diol increases expression EXP 6480464 alpha-Chlorohydrin results in increased expression of PYGL protein CTD PMID:26597043 3H-1,2-dithiole-3-thione decreases expression EXP 6480464 1, 2-dithiol-3-thione results in decreased expression of PYGL mRNA CTD PMID:19162173 4'-hydroxyacetophenone affects binding EXP 6480464 4-hydroxyacetophenone binds to PYGL protein CTD PMID:15236443 4,4'-diaminodiphenylmethane increases expression ISO RGD:731804 6480464 4, 4'-diaminodiphenylmethane results in increased expression of PYGL mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol increases expression ISO RGD:731804 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of PYGL mRNA CTD PMID:30951980 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole affects expression EXP 6480464 Omeprazole affects the expression of PYGL mRNA CTD PMID:19483382 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of PYGL mRNA CTD PMID:19483382 8-bromo-3',5'-cyclic AMP decreases expression ISO RGD:731803 6480464 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PYGL mRNA CTD PMID:22079614 acetylsalicylic acid affects binding EXP 6480464 Aspirin binds to PYGL protein CTD PMID:15236443 acrylamides affects binding ISO RGD:731803 6480464 Acrylamides analog binds to PYGL protein CTD PMID:18723356 acrylamides decreases activity ISO RGD:731803 6480464 Acrylamides analog results in decreased activity of PYGL protein CTD PMID:18723356 aldehydo-D-glucose multiple interactions EXP 6480464 Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 aluminium phosphide increases activity EXP 6480464 aluminum phosphide results in increased activity of PYGL protein CTD PMID:20929055 alvocidib affects binding ISO RGD:731803 6480464 PYGL protein binds to alvocidib CTD PMID:11368340 amiodarone affects expression EXP 6480464 Amiodarone affects the expression of PYGL mRNA CTD PMID:19483382 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of PYGL mRNA CTD PMID:16483693 arsenite(3-) multiple interactions ISO RGD:731804 6480464 arsenite inhibits the reaction [INS protein results in decreased activity of PYGL protein] CTD PMID:28952001 arsenous acid increases expression ISO RGD:731803 6480464 Arsenic Trioxide results in increased expression of PYGL mRNA CTD PMID:20458559 atrazine increases expression ISO RGD:731803 6480464 Atrazine results in increased expression of PYGL mRNA CTD PMID:22378314 benzamide decreases activity ISO RGD:731803 6480464 benzamide analog results in decreased activity of PYGL protein CTD PMID:19758809 benzbromarone affects expression EXP 6480464 Benzbromarone affects the expression of PYGL mRNA CTD PMID:19483382 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of PYGL mRNA CTD PMID:21839799 benzo[a]pyrene decreases expression ISO RGD:731804 6480464 Benzo(a)pyrene results in decreased expression of PYGL mRNA CTD PMID:22228805 bis(2-ethylhexyl) phthalate multiple interactions EXP 6480464 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of PYGL promoter CTD PMID:23359474 bis(2-ethylhexyl) phthalate increases expression ISO RGD:731803 6480464 Diethylhexyl Phthalate results in increased expression of PYGL mRNA CTD PMID:31163220 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of PYGL promoter, [bisphenol A co-treated with Estradiol] results in increased expression of PYGL mRNA CTD PMID:23359474 , PMID:26496021 bisphenol A increases expression ISO RGD:731804 6480464 bisphenol A results in increased expression of PYGL mRNA CTD PMID:30951980 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of PYGL mRNA CTD PMID:25181051 bisphenol F increases expression ISO RGD:731804 6480464 bisphenol F results in increased expression of PYGL mRNA CTD PMID:30951980 buspirone decreases expression EXP 6480464 Buspirone results in decreased expression of PYGL mRNA CTD PMID:24136188 cadmium dichloride increases expression ISO RGD:731803 6480464 Cadmium Chloride results in increased expression of PYGL mRNA CTD PMID:26472689 Calcimycin increases activity EXP 6480464 Calcimycin results in increased activity of PYGL protein CTD PMID:6430282 Calcimycin multiple interactions EXP 6480464 Calcium deficiency inhibits the reaction [Calcimycin results in increased activity of PYGL protein] CTD PMID:6430282 calcium atom multiple interactions EXP 6480464 [Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein more ... CTD PMID:6430282 , PMID:747652 calcium(0) multiple interactions EXP 6480464 [Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein more ... CTD PMID:6430282 , PMID:747652 carbon nanotube decreases expression ISO RGD:731804 6480464 Nanotubes, Carbon analog results in decreased expression of PYGL mRNA, Nanotubes, Carbon results in decreased expression of PYGL mRNA CTD PMID:25620056 chloroacetaldehyde affects expression ISO RGD:731803 6480464 chloroacetaldehyde affects the expression of PYGL mRNA CTD PMID:25596134 chloroacetic acid decreases expression ISO RGD:731804 6480464 chloroacetic acid results in decreased expression of PYGL mRNA, chloroacetic acid results in decreased expression of PYGL protein CTD PMID:28189721 chloroform decreases expression EXP 6480464 Chloroform results in decreased expression of PYGL mRNA CTD PMID:17522070 chloropicrin decreases expression ISO RGD:731803 6480464 chloropicrin results in decreased expression of PYGL mRNA CTD PMID:28476498 chloropicrin increases expression ISO RGD:731803 6480464 chloropicrin results in increased expression of PYGL mRNA CTD PMID:26352163 ciguatoxin CTX1B affects expression ISO RGD:731804 6480464 Ciguatoxins affects the expression of PYGL mRNA CTD PMID:18353800 cisplatin decreases expression ISO RGD:731803 6480464 Cisplatin results in decreased expression of PYGL mRNA CTD PMID:25596134 cisplatin increases expression ISO RGD:731803 6480464 Cisplatin results in increased expression of PYGL mRNA CTD PMID:27392435 , PMID:27594783 clofibrate affects expression EXP 6480464 Clofibrate affects the expression of PYGL mRNA CTD PMID:19483382 clofibrate decreases expression EXP 6480464 Clofibrate results in decreased expression of PYGL protein CTD PMID:16470657 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of PYGL mRNA CTD PMID:24386269 copper(II) sulfate decreases expression ISO RGD:731803 6480464 Copper Sulfate results in decreased expression of PYGL mRNA CTD PMID:19549813 cyclosporin A decreases expression ISO RGD:731804 6480464 Cyclosporine results in decreased expression of PYGL mRNA CTD PMID:19770486 cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of PYGL mRNA CTD PMID:25596134 cyclosporin A decreases expression ISO RGD:731803 6480464 Cyclosporine results in decreased expression of PYGL mRNA CTD PMID:25562108 , PMID:25596134 D-glucose multiple interactions EXP 6480464 Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 dexamethasone increases expression ISO RGD:731803 6480464 Dexamethasone results in increased expression of PYGL mRNA CTD PMID:25047013 diarsenic trioxide increases expression ISO RGD:731803 6480464 Arsenic Trioxide results in increased expression of PYGL mRNA CTD PMID:20458559 dibutyl phthalate multiple interactions EXP 6480464 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of PYGL promoter CTD PMID:23359474 dichlorvos increases activity EXP 6480464 Dichlorvos results in increased activity of PYGL protein CTD PMID:222008 dioxygen increases expression ISO RGD:731804 6480464 Oxygen deficiency results in increased expression of PYGL mRNA CTD PMID:20880076 dioxygen increases expression ISO RGD:731803 6480464 Oxygen deficiency results in increased expression of PYGL mRNA CTD PMID:25596134 dorsomorphin multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin increases expression ISO RGD:731803 6480464 Doxorubicin results in increased expression of PYGL mRNA CTD PMID:30031762 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of PYGL mRNA CTD PMID:29391264 entinostat increases expression ISO RGD:731803 6480464 entinostat results in increased expression of PYGL mRNA CTD PMID:27188386 erythromycin estolate decreases expression EXP 6480464 Erythromycin Estolate results in decreased expression of PYGL mRNA CTD PMID:17522070 fenofibrate increases expression EXP 6480464 Fenofibrate results in increased expression of PYGL mRNA CTD PMID:25596134 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of PYGL mRNA CTD PMID:24136188 glucose multiple interactions EXP 6480464 Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 ibuprofen increases expression EXP 6480464 Ibuprofen results in increased expression of PYGL mRNA CTD PMID:25596134 ifosfamide decreases expression ISO RGD:731803 6480464 Ifosfamide results in decreased expression of PYGL mRNA CTD PMID:25596134 isoprenaline increases activity EXP 6480464 Isoproterenol results in increased activity of PYGL protein CTD PMID:6430282 L-ethionine affects expression EXP 6480464 Ethionine affects the expression of PYGL mRNA CTD PMID:19483382 malathion multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Malathion results in increased expression of PYGL mRNA] CTD PMID:25449180 malathion increases expression EXP 6480464 Malathion results in increased expression of PYGL mRNA CTD PMID:25449180 metformin decreases expression EXP 6480464 Metformin results in decreased expression of PYGL mRNA CTD PMID:25596134 methylarsonite multiple interactions ISO RGD:731804 6480464 methylarsonite inhibits the reaction [INS protein results in decreased activity of PYGL protein] CTD PMID:28952001 methylmercury chloride decreases expression ISO RGD:731803 6480464 methylmercuric chloride results in decreased expression of PYGL mRNA CTD PMID:23179753 , PMID:27188386 N-acetyl-L-cysteine multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Malathion results in increased expression of PYGL mRNA] CTD PMID:25449180 N-nitrosomorpholine decreases expression EXP 6480464 N-nitrosomorpholine results in decreased expression of PYGL protein CTD PMID:2885971 N-nitrosomorpholine affects expression EXP 6480464 N-nitrosomorpholine affects the expression of PYGL protein CTD PMID:19716841 nefazodone decreases expression EXP 6480464 nefazodone results in decreased expression of PYGL mRNA CTD PMID:24136188 neostigmine increases activity EXP 6480464 Neostigmine results in increased activity of PYGL protein modified form CTD PMID:1350317 neostigmine multiple interactions EXP 6480464 Phentolamine inhibits the reaction [Neostigmine results in increased activity of PYGL protein modified form] CTD PMID:1350317 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of PYGL mRNA CTD PMID:22110744 nicotinamide multiple interactions EXP 6480464 [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein, resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 nimesulide decreases expression EXP 6480464 nimesulide results in decreased expression of PYGL mRNA CTD PMID:24136188 omeprazole affects expression EXP 6480464 Omeprazole affects the expression of PYGL mRNA CTD PMID:19483382 paracetamol affects expression ISO RGD:731804 6480464 Acetaminophen affects the expression of PYGL mRNA CTD PMID:17562736 paracetamol multiple interactions ISO RGD:731804 6480464 PANX1 gene mutant form inhibits the reaction [Acetaminophen results in decreased expression of PYGL mRNA] CTD PMID:29246445 paracetamol decreases expression ISO RGD:731804 6480464 Acetaminophen results in decreased expression of PYGL mRNA CTD PMID:29246445 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of PYGL mRNA CTD PMID:17522070 paracetamol multiple interactions ISO RGD:731803 6480464 [Dietary Carbohydrates co-treated with Acetaminophen] results in increased expression of PYGL mRNA CTD PMID:17093179 perfluorooctane-1-sulfonic acid decreases expression EXP 6480464 perfluorooctane sulfonic acid results in decreased expression of PYGL mRNA CTD PMID:19162173 perfluorooctanoic acid decreases expression EXP 6480464 perfluorooctanoic acid results in decreased expression of PYGL mRNA CTD PMID:19162173 phentolamine multiple interactions EXP 6480464 Phentolamine inhibits the reaction [Neostigmine results in increased activity of PYGL protein modified form] CTD PMID:1350317 phenylephrine multiple interactions EXP 6480464 [Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein, Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 phenylephrine increases expression EXP 6480464 Phenylephrine results in increased expression of PYGL mRNA CTD PMID:18158353 pirinixic acid affects expression EXP 6480464 pirinixic acid affects the expression of PYGL mRNA CTD PMID:19483382 potassium chromate increases expression ISO RGD:731803 6480464 potassium chromate(VI) results in increased expression of PYGL mRNA CTD PMID:22714537 pyrogallol increases expression ISO RGD:731804 6480464 Pyrogallol results in increased expression of PYGL mRNA CTD PMID:20362636 rac-lactic acid decreases expression ISO RGD:731803 6480464 Lactic Acid results in decreased expression of PYGL mRNA CTD PMID:30851411 resveratrol multiple interactions EXP 6480464 resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of PYGL mRNA CTD PMID:28374803 rotenone increases expression ISO RGD:731803 6480464 Rotenone results in increased expression of PYGL mRNA CTD PMID:29955902 SB 431542 multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 sodium dichromate decreases expression EXP 6480464 sodium bichromate results in decreased expression of PYGL mRNA CTD PMID:25993096 streptozocin multiple interactions EXP 6480464 [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein, resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 streptozocin decreases expression EXP 6480464 Streptozocin results in decreased expression of PYGL mRNA CTD PMID:25905778 tert-butyl hydroperoxide increases expression ISO RGD:731803 6480464 tert-Butylhydroperoxide results in increased expression of PYGL mRNA CTD PMID:15336504 Tesaglitazar increases expression EXP 6480464 tesaglitazar results in increased expression of PYGL mRNA CTD PMID:21515302 tetrachloromethane affects expression ISO RGD:731804 6480464 Carbon Tetrachloride affects the expression of PYGL mRNA CTD PMID:17484886 tetrachloromethane decreases expression ISO RGD:731804 6480464 Carbon Tetrachloride results in decreased expression of PYGL mRNA CTD PMID:27339419 tetrachloromethane affects expression EXP 6480464 Carbon Tetrachloride affects the expression of PYGL mRNA CTD PMID:15963342 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of PYGL mRNA CTD PMID:17522070 , PMID:31150632 tetracycline decreases expression EXP 6480464 Tetracycline results in decreased expression of PYGL mRNA CTD PMID:17522070 thimerosal decreases expression ISO RGD:731803 6480464 Thimerosal results in decreased expression of PYGL mRNA CTD PMID:27188386 thioacetamide affects expression EXP 6480464 Thioacetamide affects the expression of PYGL mRNA CTD PMID:19483382 titanium dioxide increases expression ISO RGD:731804 6480464 titanium dioxide results in increased expression of PYGL mRNA CTD PMID:23409001 titanium dioxide affects expression ISO RGD:731804 6480464 titanium dioxide affects the expression of PYGL mRNA CTD PMID:17656681 titanium dioxide decreases expression ISO RGD:731804 6480464 titanium dioxide results in decreased expression of PYGL mRNA CTD PMID:23557971 trichostatin A increases expression ISO RGD:731803 6480464 trichostatin A results in increased expression of PYGL mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA CTD PMID:27188386 Triptolide decreases expression EXP 6480464 triptolide results in decreased expression of PYGL mRNA CTD PMID:23639586 troglitazone decreases expression EXP 6480464 troglitazone results in decreased expression of PYGL mRNA, troglitazone results in decreased expression of PYGL protein CTD PMID:21315101 , PMID:21515302 tungsten decreases expression ISO RGD:731804 6480464 Tungsten results in decreased expression of PYGL mRNA CTD PMID:30912803 valdecoxib decreases expression EXP 6480464 valdecoxib results in decreased expression of PYGL mRNA CTD PMID:24136188 valproic acid increases expression ISO RGD:731804 6480464 Valproic Acid results in increased expression of PYGL mRNA CTD PMID:21427059 valproic acid increases expression ISO RGD:731803 6480464 Valproic Acid results in increased expression of PYGL mRNA CTD PMID:19101580 more ... valproic acid multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA CTD PMID:27188386 valproic acid affects expression ISO RGD:731803 6480464 Valproic Acid affects the expression of PYGL mRNA CTD PMID:25979313 vorinostat multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:731803 6480464 vorinostat results in increased expression of PYGL mRNA CTD PMID:26272509 zoledronic acid decreases expression ISO RGD:731803 6480464 zoledronic acid results in decreased expression of PYGL mRNA CTD PMID:25596134
Gene-Chemical Interaction Annotations
